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Abstract

USING STRUTURAL ANALYSIS TO INVESTIGATE THE FUNCTION OF
SUPPRESSOR OF IKK-ε (SIKE)
By Sean W. McKinley, M.S.
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2014

Major Director: Dr. Jessica K. Bell, Ph.D.
Assistant Professor, Department of Biochemistry & Molecular Biology

The innate immune system provides the body’s first line of defense against
pathogenic challenge through pathogen recognition and initiation of the immune
response. Among the various cellular mechanisms of pathogen recognition in mammals,
Toll-like receptor 3 (TLR3) recognizes viral dsRNA. Stimulation of TLR3 signaling
pathway leads to transcription of pro-inflammatory cytokines and type-1 Interferons.
Suppressor of IKKε (SIKE) interacts with two kinases in the signaling pathway, IKKε
and TANK binding kinase 1 (TBK1), inhibiting the transcription of type I interferons.
Recently, the Bell Laboratory discovered that SIKE blocks TBK1-mediated activation of
type I interferons by acting as a high affinity, alternative substrate of TBK1.

	
  

	
  
To further characterize SIKE’s function within the antiviral response, this study
focused on defining the overall SIKE structure. Using recombinant protein expressed
from E. coli and purified via immobilized metal affinity chromatography, SIKE crystals
were obtained from a sample concentrated to 15 mg/ml under several crystallization
conditions. Yet, reproducing these results has been difficult. In this study, we have
modified the purification scheme to remove an E. coli contaminant, SlyD. Purification
under denaturing conditions, removal of soluble proteins, incorporation of ion exchange
and different IMAC (immobilized metal ion affinity chromatography) resins has been
tested. For each scheme, size exclusion chromatography and SDSPAGE/Coomassie/silver stain were used to assess purity. Crystallization trials for
samples from each purification scheme were completed. In addition to crystallization
trials, hydrogen-deuterium exchange (HDX) was investigated, accompanied with pepsin
digests, in order to further characterize the dynamic structure of SIKE.
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Chapter 1: Introduction

1.1 Immunology and the Immune Response
Immunology is a subdivision of biomedical science that explores all aspects of the
immune systems found in different organisms. The main focus of this field is the
functioning of the immune system in both healthy and diseased states, as well as genetic
or acquired immune disorders1. Immunology also involves studying other systems,
where pathology and clinical symptoms are affected by immune reactions. The success
of the immune system depends on its ability to distinguish host (self) cells from foreign
(non-self) antigens. The immune system doesn’t normally mount an immune response
against itself; this is termed “tolerance”. However, in rare cases tolerance can be lost and
immune responses are initiated against the host’s cells; this is called auto-immunity1,2.
The Chinese are credited with making some of the first immunological
observations, deliberately infecting people with mild forms of small pox to prevent
infections with deadlier forms and even providing lifelong protection. After this
discovery, knowledge and practices moved through Turkey in the late 18th century and
ultimately to Britain in 1796. There, British physician, Edward Jenner, published his
long-term observation that milkmaids exposed to cowpox became protected from
smallpox1,2. In his experiments, he exposed a “healthy” 8-year-old boy to cowpox virus
taken from a milkmaid cowpox pustule by inserting pus into an incision in the boys arm2.
Cowpox shares antigens with smallpox, but doesn’t cause the same disease; the vaccine
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worked by initiating an immune response against cowpox antigen, subsequently
immunizing the boy against smallpox antigen and establishing a smallpox immunity2.
For the next fifty years, the prevailing theory was that chemical toxins were
contracted from ill patients, causing the transmission of the disease; the bacteria observed
were considered to be symptoms of the disease state, not the cause of it2. It wasn’t until
the mid-19th century that Friedrich Gustav Jakob Henle, following the ideas of Girolamo
Fracastoro and Agostino Bassi, began to observe that growth and reproduction of some
microorganisms within their hosts could be the cause of a disease. Gustav’s essay, “On
Miasma and Contagia,” was an early report demonstrating the germ theory of disease.
“Miasma” was considered to be a poisonous vapor or toxin emitted from infected organic
matter that can cause a disease. This became the predominant theory of disease
transmission until the germ theory of disease greatly changed immunology3.
Louis Pasteur is traditionally considered as the “father of modern immunology”
because of his extensive work in the late 19th century on fermentation, spontaneous
generation, and other areas of microbiology4. Pasteur led the fields of epidemiology,
bacteriology, and public health in that time, as well as being the first to establish the
possibility of anaerobic organisms5. In his famous work, “Germ Theory of Disease,”
Louis Pasteur explained his theory that some infectious diseases, such as anthrax,
cholera, tuberculosis, and smallpox, are caused by microorganisms. Pasteur is also
renowned for inventing a rabies vaccine in 18854.
In 1876, Louis Pasteur’s “Germ Theory of Disease” was proven when Robert
Koch successfully isolated an infectious bacillus that he showed was the cause of both
anthrax and cholera. Koch investigated pathogenicity, developing a set of postulates that
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are still used in labs today to examine if a disease is caused by a specific virus, bacteria,
fungi, or parasite. Koch also worked extensively to develop more efficient staining
methods, culturing techniques, and was one of the first to demonstrate that unfavorable
conditions can lead to sporulation in certain bacterial strains to survive6.
After the breakthrough that diseases are caused by microbes, researchers began
investigating how host organisms combat these diseases and symptoms. In 1890, Emil
von Behring and Shibasaburo Kitasato immunized guinea pigs with heat-treated
diphtheria toxin; by infecting the animals with a non-lethal form of the pathogen, they
were able to develop a sufficient immune response to subsequent infections by those
bacteria. After its success in the first human trial, it was known as the “first cure” and
Von Behring was awarded the Nobel Prize in 1901 for this work7.
Other scientists at this time were also researching different cellular processes.
Russian zoologist, Elie Metchnikoff, discovered the process of phagocytosis while
working with starfish larvae. He realized that this was practically the same process that
white blood cells perform in the human body to destroy certain potentially harmful
microbes. This belief was argued by some of the leading scientists such as Pasteur;
however, Metchnikoff’s work on phagocytosis won him the Nobel Prize in 19088.
Debates arose as to which theory regarding the cellular basis of immunity was
correct: antibody-mediated immunity or phagocytosis. Today, they are both recognized
as fundamental processes of cellular immunity. The antibody-mediated response is
associated with the acquired (adaptive) immune response and requires the production of
specific antibodies to target a particular pathogen. Germline-encoded gene segments
have the ability to recombine to synthesize copious amounts of unique, antigen-
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recognizing immunoglobulin9. This adaptability process requires 3-5 days to complete,
following the initial infection; however, can result in lifelong immunity to subsequent
infections by pathogens expressing the same antigen2 (shown in Figure 1).
The other process of cellular immunity, phagocytosis, plays a primary role in,
what is now known as, the innate (non-specific) immune response. This begins
immediately after infection and provides the first line of defense against other organisms
in a non-specific manner. These responses are mostly limited to defenses that are
constitutively expressed and readily mobilized1,2. Germline encoded sensors and
receptors recognize certain signals and stimulate phagocytic cells to engulf and kill the
pathogens associated with these signals2. The innate immune system involves anatomical
barriers such as epithelial surfaces, low pH levels, and normal flora that prevent infection
and colonization by invading organisms. It also contains humoral barriers, for example
the complement system, interferons, interleukins, and lysozyme, which work as part of
the inflammatory process when invasive pathogens penetrate tissues. As proposed by
Metchnikkoff, neutrophils, macrophages, Natural Killer (NK) cells, and eosinophils
perform the cellular process of phagocytosis. These cells are recruited to the site of
infection where they kill invading organisms extracellularly or phagocytose and kill them
intracellularly1,2. The main focus of our lab, and the remainder of this document, is the
role of the innate immune system and the function of a newly discovered component of
the anti-viral immune response.
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Figure 1: Main components of the innate and adaptive immune systems
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Figure	
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1.2 The Innate Immune System
The human body encounters various pathogenic agents each day, yet infections
are rarely established. These agents are destroyed within minutes to hours without the
use of antigen-specific immunoglobulin for recognition1. The innate immune response
employs a set of mechanisms to distinguish self from non-self that are thought to be
older, evolutionarily3. These defense strategies are comprised of anatomical, humoral,
and cellular barriers, all of which contribute to the first line of defense against
pathogens3.
Anatomical barriers provide the earliest protection of the innate defense
systems1,2. These anatomical barriers are characterized by certain mechanical, chemical,
and biological factors. Mechanical barriers refer to the epithelial surfaces that form a
physical barrier that is impermeable to most infectious agents. These epithelial layers
include the skin and lining of respiratory, gastrointestinal, and urinary tracts and are held
together by tight junctions1,2. Mechanisms used by these barriers to remove bacteria and
other infectious agents include: desquamation (or shedding) of the skin, oscillation of
broncho-pulmonary cilia to clear respiratory tract, and the flushing of tears and saliva to
protect the mouth and eyes3. Biological factors, such as normal microbial flora, function
to prevent the colonization of pathogenic bacteria through various methods. Flora is
commensal bacterium that can inhibit the establishment of bacterial infections by
secreting toxic substances or by competing for nutrients or attachment to epithelial
surfaces1. These commensal bacteria can also stimulate the nearby epithelial cells to
secrete antimicrobial agents to ward off invasive organisms. Chemical factors
complement the mechanical barriers in the innate immune response. Lysozyme and
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phospholipase help break down the cell wall of bacteria and destabilize bacterial
membranes. These are found in saliva, tears, and nasal secretions. Fatty acids and low
pH levels inhibit the growth of bacteria and are found on the skin and in the
gastrointestinal tract. Defensins are antimicrobial agents found in the lungs and
gastrointestinal tract that destroy microbial cell membranes1,2. All together, these
physical, chemical, and biological barriers provide the first stage of defense in the innate
immune response.
Infections, however, can still occur when damage has been done to tissues and
anatomical barriers are breached. When a microbe has established an infection, the next
system of defense employed by the innate immune system is the anti-inflammatory
response. This process involves humoral factors like the complement system,
coagulation system, interferons, interleukins, lysozyme, and lactoferrin/transferrin1,2.
These factors are constitutively present in serum and are also up-regulated at the site of
infection, once the infection is recognized by host cells. The complement system is the
major non-specific defense mechanism that, once activated, leads to vasodilation,
recruitment of phagocytic cells, and opsonization and lysis of the organism1. The
coagulation system is often activated in situations that involve more tissue damage.
Products of the coagulation system increase vascular permeability, attract phagocytic
cells to the site of infection, and can have direct anti-microbial properties. Lactoferrin
and transferrin both function by binding iron in the environment. This is essential for
bacterial growth and helps prevent infections. The release of interferons helps to limit
viral replication in infected cells and lysozyme works to break down bacterial cell walls.
Interleukins function to induce a fever and initiate the production of acute phase proteins
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that can have antimicrobial properties. These factors are present in serum play an
important role in the inflammation process, once infections have been established.
The cellular functions of the innate immune system include the recruitment of
polymorphonuclear (PMN) eosinophils and macrophages to the site of infection.
Neutrophils are a type of PMN cell that are recruited to the site of infection to
phagocytose invading organisms and kill them intracellularly1. Macrophages function
using phagocytosis and intracellular killing, as well as extracellular killing of infected or
dysfunctional host cells. Macrophages also contribute to antigen presentation that is
required for the induction of specific immune responses. Natural Killer (NK) cells
contribute to the killing of virally infected and tumor cells. Eosinophils contain proteins
that are effective in killing certain infectious parasites3. Along with mechanical and
humoral factors, the cellular defense systems provide a short-lived, non-specific, early
immune response to control or eliminate infection by pathogenic agents.

1.3 Toll-like receptors: Discovery and Structure
The innate immune system uses a unique strategy in order to distinguish self from
non-self antigens using non-specific means. Repeating patterns on the pathogen surface
structure or in nucleic acid sequences are recognized by pattern recognition receptors
(PRRs). These receptors identify evolutionarily conserved motifs that are found mainly
in microorganisms, called PAMPs (pathogen-associated molecular patterns) 1,2,11. PRRs
are expressed by various epithelial, endothelial, and immune cells and immediately begin
mounting an immune response. Receptors are organized into categories defined by their
location and function: membrane-bound signaling receptors, cytosolic signaling
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receptors, membrane-bound phagocytic receptors, or free receptors secreted into the
circulatory or lymphatic systems1,2. One class of signaling receptors, Toll-like receptors
(TLRs), is the focus of research in the Bell Laboratory and will be the basis of the
remainder of the document.
TLRs represent an evolutionarily conserved defense system. First identified in
fruit fly embryos, Toll receptors functioned in dorso-ventral patterning during
embryogenesis. Christine NÜsslein-Volhard observed underdevelopment in the
patterning when mutated; her reaction was “Das was ja toll!” meaning, “That was weird!”
which subsequently gave Toll receptors their name10. The protein product of the Toll
gene that causes ventral patterning in fruit fly embryos, known as Dorsal, is a fly
homologue of the transcription factor NF-κB1,2. Jules Hoffman observed these mutations
in adult fruit flies and observed decreased production of antimicrobial peptides and
increased susceptibility to fungal infections1,10. This was the first time Toll receptors
were associated with the host immune system. Homologues (Toll-like receptors) were
then identified in mammals by Ruslan Medzhitov and Charles Janeway, and shown to
function in several host defense mechanisms 1,2,10. The group determined that TLR
activation induces NF-κB in a similar manner as interleukin-1 receptors (IL-1Rs) and the
fruit fly Toll receptors, leading to the expression of inflammatory cytokines2,11.
To date, at least 10 members of the TLR family have been identified in mammals
and are part of a larger superfamily of interleukin-1 receptors (IL-1Rs). The members of
this superfamily all have a conserved region of about 200 amino acids in the cytoplasmic
(C-terminal) region termed the TIR (Toll/IL-1R) domain11. This suggests that both TLRs
and IL-1Rs signal via shared downstream molecules10,11. These TIR domains are also
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observed in plants, which may be evidence that this is a conserved motif that may have
served immune functions prior to the divergence of plants and animals.
In contrast, the extracellular (N-terminal) regions of these TLRs contain leucinerich repeats (LRRs), while IL-1Rs have three immunoglobulin domains, which function
to bind ligands. These extracellular domains are highly variable and are directly involved
in the recognition of a variety of pathogens1,11,12. Scientists next sought to identify which
type of ligands stimulate the receptors: a “danger signal” produced by host cells or a
microbial molecule released by the pathogen10. Alexander Poltorak and Bruce Beutler
observed that were unresponsive to a gram-negative endotoxin component, LPS, which
they mapped back to a mutation in the TLR4 gene. To date, the structures of TLR1-6 and
TLR8 have been solved using x-ray crystallography13. The variable, extracellular
domains could now be analyzed to determine the amino acids underlying the
receptor:ligand interactions. Three-dimensional structure showed that the LRR domains
consist of a varying number of repeats, each 22-29 amino acids in length, containing the
motif XXLXLXX along with other conserved leucines2,11,13. These domains also contain
hydrophobic residues spaced at distinct, conserved distances, pointing inward and
forming a solenoid structure. TLRs are able to form either homo- or heterodimers,
depending on the type of ligand. Each of the ten members of the TLR family recognize a
variety of evolutionarily conserved PAMPs, such as (but are not limited to) lipopeptides
(TLR2:TLR1 or TLR2:TLR6 heterodimers), double-stranded RNA (TLR3 homodimer),
LPS (TLR4 homodimer), flagellin (TLR5 homodimer), single-stranded RNA (TLR7 and
TLR8 monomer), or CpG-rich unmethylated DNA (TLR9 homodimer) (Figure 2) 1,10,11,12.
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Signal transduction through TLRs can occur both on the cell surface and in

intracellular vesicles. TLRs 1, 2, 4, 5, and 6 are located mainly on the cell surface, while
3, 8, and 9 are found on the membranes of endosomes and lysosomes13 (Figure 2). Signal
transduction for both occurs in the cytosol, allowing their ligand-binding domains to be
exposed to either vesicular contents or the extracellular environment. Surface TLRs
interact largely with microbial membrane components while endosomal TLRs are able to
interact with genetic material from pathogens that have been internalized and broken
down13. Many different types of pathogens can be detected despite the mechanism used
to establish infections.
TLR expression is complex and differs between cell types. Expression is most
significant in different white blood cell types such as macrophages, mast cells, and
dendritic cells. This allows macrophages and mast cells to initiate innate immune
responses and dendritic cells to initiate adaptive immune responses13. Ultimately, TLR
signaling leads to activation of interferon regulatory factors (IRFs), activator protein
1(AP-1), or NF-κB transcription factor family members. These transcription factors are
responsible for producing the antimicrobial effects; NF-κB and AP-1 mainly induce
expression of pro-inflammatory cytokines and chemotactic factors while IRFs induce
expression of antiviral type1 interferons1. The location and activating-ligand of each TLR
define what products are expressed, antiviral or antibacterial.
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Figure 2: Human Toll-like receptors and antigens they recognize.
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1.4 Toll-Like Receptor 3: Role in Innate Immunity
The TLR of the pathway focused on for these studies, TLR-3, is expressed among
different cell types1,2. As previously mentioned, TLR-3 is found on the membranes of
endosomes and lysosomes and detects genetic material exposed after the pathogen has
been internalized and digested. Among all of the Toll-like receptors, it is the only one
that is capable of recognizing dsRNA14. Once the vesicular material is identified as
foreign, a signal is generated to activate transcription factors to initiate an innate immune
response is initiated.
Mammalian TLRs are active when ligand-binding stimulates formation of dimers
or oligomers3. Ligand-induced dimerization of two TLR-3 ectodomains brings the two
cytoplasmic TIR domains into close proximity, allowing them to interact with specific
adaptor molecules that initiate the intracellular signaling1,2,11. Combinational use of
different adaptor molecules allows for diverse and distinct biological effects of activating
different toll-like receptors. Four adaptor molecules used by TLRs are: myeloid
differentiation factor 88 (MyD88), MyD88 adaptor-like (MAL), TIR domain-containing
adaptor-inducing IFN-β (TRIF), and TRIF-related adaptor molecule (TRAM)1,11. While
other TLRs may use one or more of them, TLR-3 interacts with only one, TRIF, to
induce activation of NF- κB and MAPK (mitogen-activated protein kinases) in MyD-88deficient macrophages11.
TRIF is the most crucial adaptor protein in the TLR-3 pathway and also provides
a connection to a branch of TLR-4 signaling that converges downstream in the TLR-3
pathway15. Overexpression or deficiencies of TRIF alone can have adverse effects on the
immune response generated by those TLR pathways15. TRIF has distinct protein-
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interaction motifs that allow the recruitment of various effector proteins, which results in
one of at least three possible signaling cascades for TLR-3 activation (Figure 3)1,2.
Two of the three possible signal cascades initiated by TLR-3 activation involve
the recruitment of TRIF, however, one results in NF-κB expression, while the other
induces IRF-31,2,15. TRIF recruits TRAF-6 to its N-terminal domain via a specific TRAF6-binding sequence, which leads to the recruitment of RIP1 (receptor-interacting protein
1) kinase to the C-terminal domain of TRIF through interaction of their RIP homotypic
interaction motifs (RHIMs)1,15,16. At this point, the two pathways diverge depending on
the ubiquitination state of RIP1.
If ubiquitination of lysine 377 on RIP1 kinase does not occur, it will trigger a cell
death-associated response. FADD (Fas-Associated with Death Domain protein) and
Caspase 8 are recruited to complex with RIP1 to initiate downstream signaling.
Activation of Caspase 8 leads to promotion of cell death by triggering the receptormediated apoptotic pathway2,16. This outcome suggests that this pathway is an important
host defense for limiting the spread of viral infections16.
Ubiquitination of Lysine residue 377 on RIP1 initiates recruitment and binding of
ubiquitin acceptor proteins, TAK1 (transforming growth factor β-activating kinase 1) and
TAB2 (TAK binding protein 2)15,16. Activation of TAK1 causes the complex to be
released in the cytoplasm to phosphorylate, and activation IKK (IκB kinase complex), a
heterodimer composed of IKKα and IKKβ subunits, as well as activate of NEMO (NF-κB
essential modulator). In turn, the activated IKK complex phosphorylates two serine
residues of IκBα (Inhibitor of κBα), which is normally sequestering NF-κB complex,
RelA (p65) and NF-κB1, in a dormant state until this modification15,16. Phosphorylation,
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along with further ubiquitination, targets IκBα for degradation by proteasome and allows
translocation of the NF-κB complex into the nucleus. Once in the nucleus, it functions
as a transcription factor, inducing the expression of genes involved in the immune
response, cellular growth and survival responses, as well as forming an inhibitory
feedback loop by up-regulating the expression of its own receptor, IκBα2,16,17.
The third signaling cascade requires the recruitment of effector molecules TRAF1
(tumor necrosis factor receptor-associated factor 1), TRAF2, TRAF3, and TRAF61,2,15,16.
These proteins mediate the signal transduction pathway by functioning as molecular
bridges that bring other effector proteins together. Once recruited to the activated
receptors, these proteins mediate the activation of TBK1 (TANK-binding kinase 1)1,2.
Exclusive interactions of three adaptors: TANK (TRAF-associated NK-κB inhibitor),
NAP1 (NF-κB activating kinase (NAK)-associated protein 1), and SINTBAD (similar to
NAP1 TBK1 adaptor), with two kinases: TBK1 and IKKε (IκB kinase epsilon), leads to
activation of these kinases2,15,16. TBK1 and IKKε are responsible for phosphorylation
and activation of certain transcription factors such as IRF-3 and IRF-7. Seven Ser/Thr
sites can be phosphorylated near the C-terminus of IRF3, 385SSX9SXSXXXSXTS405.
Phosphorylation of Ser-396 to Ser-405 induces interaction with CBP/p300, while
phosphorylation of Ser-385 and Ser-386 activates IRF3 dimerization. Once it is activated
and forms a dimer, IRF3 can transmit the signal into the nucleus to initiate the antiviral
immune response through regulation of type 1 interferons1,2,15,16. These interferons (IFNα and IFNβ) help stimulate macrophages and NK cells to either elicit an anti-viral
response or a positive feedback loop by binding the IFNα/β receptors to activate the JAK
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(Janus Kinase)/STAT (signal transducer and activator of transcription) pathway and
expression of more anti-viral genes2,15.
These three TLR-3-mediated signaling pathways initiate recruitment of immune
cells, inhibition of pathogen replication, induction of apoptosis, and communication of
danger signals to nearby cells. Because of its importance in innate immunity, our work
has focused on the pathway involving IRF3 activation, the transcription factor that
functions in production of type 1 interferons. In particular, we have examined the
structure of a recently identified protein, which is known to play a role in this pathway.
SIKE is found in phosphorylated and un-phosphorylated states; the functions of both
remain unknown. As such, understanding the structure of SIKE may provide insight into
its function in the TLR-3 pathway.
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Figure 3: TRIF-dependent signaling cascades
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1.5 Suppressor of IKK-ε (SIKE): Discovery, Structure, and Function.
Several innate immune signaling pathways converge to activate TBK1, as
previously mentioned, through receptor-mediated pathogen detection. Dysregulation of
TBK1 has been linked to cancers and autoimmune disorders, intensifying the need to
understand the regulatory mechanisms used by the proteins in these pathways2,18. Known
mechanisms that modify the activity of TBK1 involve altering TBK1 ubiquitination or
masking phosphorylation sites by interacting proteins in the cascade18,19. Investigating
the functions of such interaction partners can reveal information about how the pathway
is regulated in normal environmental conditions.
Using a yeast two-hybrid screen with a human B-cell cDNA library and IKKε as
bait, a previously unknown interaction protein was identified and dubbed SIKE (for
suppressor of IKKε)19. SIKE is a 207-amino acid protein encoded by a gene that maps to
human chromosome 1p13.22,18. GenBank database searches identified SIKE as an
evolutionarily conserved protein that is part of an uncharacterized family of proteins like
fibroblast growth factor receptor 1 oncogene partner 2 (FGFR10P2), which mapped to
chromosome 12p12.12,18,20. Although SIKE differs from FGFR10P2 by 40 amino acids,
they were shown to be about 50% homologous. Additionally, studies showed that
FGFR10P2 has the ability to dimerize, associate with coiled-coil structures, and interact
with cytoskeleton networks of fibroblasts to enhance oral wound healing18,19,20. Since
coiled-coil motifs are known to mediate protein-protein interactions, researchers
questioned if SIKE could oligomerize. Analysis of SIKE revealed that it had three
predicted coiled-coil domains, two of which were high probability predicted domains
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(amino acids 72-102 and 163-197)2,18,19. Co-immunoprecipitation experiments showed
that SIKE could interact with itself to form homodimers and oligomers (Figure 4)19.
It was shown that SIKE formed interactions with IKKε, however, this kinase is
not detectable under basal physiological conditions, but is induced by activated immune
cells. Researchers then questioned whether SIKE could interact with TBK1, which is
constitutively expressed in most cell types. Co-immunoprecipitation assays showed that
SIKE not only interacted with TBK1 under physiological conditions, but it was revealed
that the high probability coiled-coil domains of SIKE (amino acids 72-207) interacted
with the coiled-coil domains of TBK1 (amino acids 601-729)19. This suggests that the
coiled-coil motifs did mediate interactions between these two proteins. It also shows that
the first 72 residues of SIKE are not necessary for interactions with TBK1, but failed to
show any interactions between SIKE and the kinase domain of TBK12,19.
In mammalian overexpression systems, it was shown that SIKE associates with
TBK1 in untransfected cells, but dissociates upon viral infection or TLR3 stimulation18,19.
Data indicated that SIKE did not disrupt any interactions required by proteins for TLR3mediated NF-κB activation, suggesting that SIKE specifically inhibited the IKKε- and
TBK1-mediated IFN-β activation pathways19. Subsequent research performed by Andrei
Medvedev’s group indicated that LPS-induced pathway activation increased levels of
SIKE mRNA, which suggests that transcription factors activated by these pathways
control SIKE expression21.
Aiming to characterize the competition between TBK1 substrates, IRF3 and
SIKE, the Bell Laboratory showed that SIKE acts as a mixed type inhibitor with respect
to IRF3 phosphorylation18. Data showed that both substrates had similar Km values (~50
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nM) at low concentrations, but SIKE displayed a Km more than 8 times lower (IRF3 = 3.5
µM; SIKE = 0.4 µM) at higher substrate concentrations. In other words, at higher
concentrations, TBK1 has a higher affinity for phosphorylating SIKE than IRF3, thus
inhibiting IRF3 dimerization, translocation into the nucleus, and regulation of Type 1
interferon gene transcription. It was also shown that SIKE is phosphorylated at six sites
that mimic the phosphorylation motif of IRF3. This phosphorylation modulates
TBK1:SIKE interactions and correlates with the initiation of the antiviral response18.
Once SIKE has been phosphorylated, the affinity of TBK1 for SIKE reduces drastically,
allowing dissociation of the two proteins. Currently, the function of phosphorylated
SIKE remains unknown. Using these findings, the Bell Lab proposed that SIKE
functions, not as an inhibitor of TBK1-mediated phosphorylation of IRF3, but as a
higher-affinity TBK1 substrate (Figure 5). Due to the fact that phosphorylation requires
enormous amounts of energy and can cause immense changes in a proteins structure, the
basis of this research is to investigate the function of phosphorylated SIKE once it has
been released by the TBK1.
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Figure 4 Hypothesized domain organization of SIKE and its kinase, TBK1.
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Figure 5: SIKE interactions in the TLR3 signaling pathway (Jessica K. Bell).
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In the TLR3 signaling cascade, SIKE is known to function as a TBK1 substrate and
subsequently inhibiting phosphorylation of IRF3. The function of SIKE once it has been
phosphorylated remains unknown.
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1.6 Current Study
To fully comprehend the function of proteins in a cellular mechanism or pathway
requires in-depth knowledge of their overall structure and amino acid composition.
Simply knowing pieces of this can only be suggestive of a protein’s function1,18,22.
Primary amino acid sequences can be used to predict secondary structural elements such
as membrane-spanning α-helices. However, a tertiary structure cannot be reliably
deduced unless the sequence is very similar to a protein whose three-dimensional
structure is already known22. A protein’s function can be predicted using other methods,
such as cellular localization, identifying charged surface areas, or locating any active sites
or catalytic pockets1,22. The main technique used to uncover three-dimensional structures
at atomic level is X-ray crystallography.
To further characterize SIKE’s function within the antiviral response, this study
focused on defining the overall SIKE structure through X-ray crystallography. To
accomplish this, the Bell lab created different constructs in hopes to increase chances of
obtaining crystals. Two of the constructs were: a full-length SIKE construct (SIKE FL)
and a construct that has had the first 71 amino acids removed (SIKE 72); these were the
two used for this study. Mutations from serine to alanine were performed on TBK1
phosphorylation sites for each SIKE construct, known as S6A. This was shown to make
SIKE more stable and reduced the number of species present in SEC (size exclusion
chromatography). Using recombinant protein expressed from E. coli and purified via
immobilized metal affinity chromatography, SIKE crystals were previously obtained
from a sample concentrated to 15 mg/ml under several crystallization conditions. Yet,
reproducing these results has been difficult.
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In this study, we have modified the purification scheme to remove an E. coli

contaminant, SlyD. Purification under denaturing conditions, removal of soluble
proteins, incorporation of ion exchange and different IMAC resins were tested. For each
scheme, size exclusion chromatography and SDS-PAGE/Coomassie/silver stain were
used to assess purity. Crystallization trials for samples from each purification scheme
were completed. In addition to crystallization trials, Hydrogen-Deuterium exchange was
investigated, accompanied with pepsin digests, in order to further characterize the
dynamic nature of SIKE structure. While these studies investigate the properties of
recombinant SIKE using various methods, the findings as a whole establish a previously
undefined protocol for SIKE purification that will improve future studies, as well as
expanding our knowledge of the surface structure of SIKE, which will enhance our
understanding of its function in the innate immune system.
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Chapter 2: Materials and Methods

2.1 Bacterial Constructs and Recombinant SIKE expression
Constructs used in this study: Full-length SIKE, SIKE 72-207, and their
corresponding S6A constructs were previously reported2. For construct expression,
recombinant pET15b vectors were transformed into BL21-CodonPlus (DE3)-RIPL
competent E. coli cells following the manufacturer’s protocol (Agilent Technologies).
A culture of Luria broth (LB) and 100µg/mL ampicillin was inoculated with a
single colony and left to incubate overnight, shaking at 200rmp at 37oC. The following
day, sub-cultures (1:100 dilution) were made in 2-1L flasks containing LB and 100µg/mL
ampicillin and incubated at 37oC, shaking at 200rpm until they reached an A600≈0.6. At
this point, each 1L culture was induced using 1mL of 1M isopropyl-β-galactopyranoside
(IPTG) and allowed to grow for another 4 hours in the same conditions before harvesting
the cells. In addition to those conditions, we investigated the effects of slowing down
growth by icing for 30 minutes pre-induction, inducing with IPTG, and incubating at
16oC (200rpm) overnight before harvesting the cells.
Overnight Express™ Instant LB (auto-induction media) was also used to culture
bacteria that had been transformed with SIKE constructs. Prepared using manufacturer’s
protocol (Novagen), 2-1L cultures of auto-induction media (100µg/mL ampicillin) were
inoculated, 1:100, using the same regular LB overnight culture grown to an A600≈0.6, as
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previously mentioned for the normal LB prep. These 2L cultures were left to incubate
overnight at 37oC, shaking at 200rpm (no IPTG is needed to stimulate protein expression
using auto-induction media).

2.2 Harvesting Inclusion Bodies
2.2.1 Chemical Lysis
Cells were harvested by centrifugation at 7,000rpm for 20 minutes at 4oC. Pellet
was collected and solubilized in a guanidine hydrochloride (GudHCl) buffer (6M
guanidine hydrochloride, 100mM sodium phosphate (pH8.0), 500mM NaCl, and 1mM 2mercaptoethanol) and brought to a pH of 8.0. After stiffing to solubilize the pellet, cell
lysates were pelleted through centrifugation at 12,000rpm for 30 minutes at 4oC. The
supernatant was mixed with 5mL resin that had been pre-equilibrated in GudHCl buffer.

2.2.2 Freeze-thaw Lysis
Cells were lysed using a freeze-thaw technique. Cell pellet was suspended in
Buffer 1 (100mM sodium phosphate (pH8.0), 500mM NaCl, and 1mM 2mercaptoethanol) with added protease inhibitors (complete EDTA free, Roche). Once in
solution, tubes were placed in an ethanol/dry ice bath until frozen and then placed in 37oC
water bath until thawed. This process was repeated two additional times and then the cell
lysate was spun down at 14,000rpm for 15 minutes at 4oC. Pellet was suspended once
more in Buffer 1 and centrifugation was repeated. Pellet was collected and re-suspended
in GudHCl lysing buffer, stirring at room temperature for one hour. Cell lysates were
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pelleted through centrifugation at 12,000rpm for 30 minutes at 4oC. Supernatant was
then mixed with 5mL resin that had been pre-equilibrated in GudHCl buffer.

2.2.3 Sonication Lysis
A third technique used to harvest SIKE from the transformed cells was sonication.
Pellet was suspended in ~75mL Buffer 1 with added protease inhibitors. While on ice,
cells were sonicated for 30 seconds (100% power). This was repeated 10-15 times,
waiting 1 minute between each sonication, and the resulting lysate was pelleted in a
centrifuge at 12,000rpm for 20 minutes at 4oC. Pellet was suspended once more in
Buffer 1 and centrifugation was repeated. Pellet was collected and re-suspended in
GudHCL buffer, stirring at room temperature for one hour. Cell lysates were pelleted
through centrifugation at 12,000rpm for 30 minutes at 4oC. Supernatant was then mixed
with 5mL resin that had been pre-equilibrated in GudHCl buffer.

2.3 Refolding Denatured SIKE
2.3.1 Ni-NTA Affinity Resin
Ni-NTA agarose resin (Qiagen) was used to bind recombinant protein construct
containing an N-terminal 6xHistadine tag (pET15b). 5mL of resin was pre-equilibrated
in the same lysing buffer as the cell lysate. The cell lysate was then added to the resin
and left on a rotator for at least one hour at room temperature to batch-bind. Resin-lysate
mixture was loaded into a BioRad Econo column and washed with 150mL GudHCl
buffer. Protein bound to the resin was refolded on the column using a 40-column-volume
(CV) reverse gradient of GudHCl buffer to Buffer 1 and eluted using 6 column volumes
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of elution buffer (Buffer 1 with 500mM imidazole); 6-5mL tubes were collected on ice
and stored at 4oC.

2.3.2 TALON® Affinity Resin (ClonTech)
IMAC using refolded protein was performed using one NiNTA elution fraction
(E3) that had been dialyzed into TALON® Buffer 1 (50mM sodium phosphate, 300mM
NaCl, and 1mM 2-mercaptoethanol) to remove imidazole. This was then combined with
TALON® resin that had been pre-equilibrated in the same TALON® Buffer 1 and left to
rock at room temperature for at least one hour at room temperature. The mixture was
loaded into a BioRad Econo column and washed with 150mL TALON® Buffer 1.
Protein bound to the resin was eluted using 6 column volumes of TALON® elution
buffer (TALON® Buffer 1 with 500mM imidazole); 6-5mL tubes were collected on ice
and stored at 4oC.
IMAC was performed on TALON® resin with denatured protein, using the same
procedure used for the NiNTA resin, however, the lysing buffer (6M Guanidine
Hydrochloride, 50mM sodium phosphate, 300mM NaCl, and 1mM 2-mercaptoethanol)
and Buffer 1 deviated, slightly, from the Ni-NTA buffers. Once the cells had been
harvested and resin had been pre-equilibrated in the lysing buffer, they were combined
and left on a rotator at room temperature for at least one hour. Resin-lysate mixture was
loaded into a BioRad Econo column and washed with 150mL TALON® lysing buffer.
Protein bound to the resin was refolded on the column using a 40-CV reverse gradient of
TALON® lysing buffer to TALON® Buffer 1 and eluted using 6 column volumes of

	
  

	
  

29	
  

TALON® elution buffer (TALON® Buffer 1 with 500mM imidazole); 6-5mL tubes were
collected on ice and stored at 4oC.

2.4 Purifying and Concentrating Proteins
2.4.1 Size Exclusion Chromatography
Each elution fraction was centrifuged at 14,000xG for 15 minutes to remove any
precipitate before being loaded on a HiLoad 16/60 Superdex 200 column (GE
Healthcare) to separate the remaining contents by size. The buffer used in filtration was:
50mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 500mM NaCl, and
1mM 2-mercaptoethanol. Peak fractions were collected and protein was screened for
using SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) analysis
and gels were silver stained to confirm purity. Pure fractions of each SIKE species were
combined and concentrated for crystallization trials.

2.4.2 Anion Exchange
Using dialysis tubing with a 10,000 Dalton molecular weight cut off, IMAC
elution fractions were dialyzed overnight in a low-salt ethanolamine buffer (50mM
ethanolamine (pH9.0), 50mM NaCl, and 1mM 2-mercaptoethanol) and then loaded on
MonoQ XL ion chromatography column (GE healthcare) to separate remaining contents
by anion exchange. Buffer salt concentration was gradually increased to 1M as fractions
were collected; protein purity was screened using SDS-PAGE and silver staining
techniques. Pure fractions from each SIKE species were combined and concentrated for
crystallization trials.
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2.4.3 Cation Exchange
Using dialysis tubing with a 10,000 Dalton molecular weight cut off, IMAC
elution fractions were dialyzed overnight in a low-salt sodium acetate buffer (50mM
sodium acetate (pH 4.5), 50mM NaCl, and 1mM 2-mercaptoethanol) and then loaded on
HiTrap SP XL ion chromatography column (GE healthcare) to separate remaining
contents by cation exchange. Buffer salt concentration was gradually increased to 1M as
fractions were collected; protein purity was screened using SDS-PAGE and silver
staining techniques. Pure fractions from each SIKE species were combined and
concentrated for crystallization trials.

2.4.4 Concentration via Centrifugation
Purified SEC fractions containing the same species were combined into one tube
and stored at 4oC. Using Amicon Ultra Centrifugal Units® from Millipore (10,000
Dalton molecular weight cut off), pooled fractions were concentrated to 15mg/mL (or as
close as possible) using the manufacturers protocol. Protein concentration was quantified
using absorbance at 260nm and 280nm. Concentrating was stopped when 15mg/mL was
reached or when precipitate was visible. To minimize precipitate formation, 1mM 2mercaptoethanol or 10% glycerol was added and mixed thoroughly before continuing
centrifugation. When complete, the concentrated sample was transferred to a sterile,
Eppendorf® LoBind protein micro-centrifuge tube and stored at 4oC.
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2.4.5 Concentration via Lyophilization (or Cryodesiccation)
Purified SEC fractions containing the same species were combined into one tube
and stored at 4oC. Using dialysis tubing with a 10,000 Dalton molecular weight cut off,
the pooled fractions were dialyzed for 24 hours in buffer containing 20mM ammonium
bicarbonate and 1mM 2-mercaptoethanol. Solution was then added to a round-bottom
flask and attached to a lyophilizer to freeze-dry overnight (0.090 mBar and -46oC). The
protein-containing powder was collected and solubilized in gel filtration buffer or 50mM
phosphate buffer (for crystallization trials or MALDI-TOF analysis respectively) and
brought up to a concentration of 15mg/mL. Protein concentration was quantified using
absorbance at 260nm and 280nm.

2.5 Crystallization trials
2.5.1 Optimized Crystallization Conditions
Previously, the lab sent samples of protein to Hauptman Woodward Institute’s
(HWI) high-throughput screening laboratory to prepare crystal-growth screening
experiments in 1536-well microassay plates. Conditions that resulted in the best crystal
formation (Table 1) were recorded and optimized in the lab with the purpose of obtaining
X-ray diffraction quality crystals. All three of the HWI screen hits were subjected to fine
grid screens to optimize crystal growth, altering the pH and PEG (polyethylene glycol)
concentration as shown in Table 2.
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Table 1: HWI Protein Crystallization Screen hits

	
  

HWI Crystal Screen Hits

Buffer (0.1M)

Salt (0.1M)

Precipitant (40% w/v)

pH

337

Magnesium chloride hexahydrate

Sodium acetate

Polyethylene glycol 8,000

5.0

371

Magnesium nitrate hexahydrate

Sodium acetate

Polyethylene glycol 4,000

5.0

863

Calcium chloride dihydrate

Sodium acetate

Polyethylene glycol 4,000

5.0
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Table 2: PEG percentage and pH for the 16 optimized crystallization conditions
30% PEG 35% PEG 40% PEG 42% PEG
pH 5.1
pH 5.1
pH 5.1
pH 5.1
30% PEG 35% PEG 40% PEG 42% PEG
pH 5.0
pH 5.0
pH 5.0
pH 5.0
30% PEG 35% PEG 40% PEG 42% PEG
pH 4.8
pH 4.8
pH 4.8
pH 4.8
30% PEG 35% PEG 40% PEG 42% PEG
pH 4.6
pH 4.6
pH 4.6
pH 4.6

	
  

	
  

34	
  

2.5.2 Paraffin Oil Drop
Crystallization Trays were set up using 72-well Terasaki Plates (Greiner BioOne). Wells were submerged using ~8mL of Paraffin oil before adding 2µL of each
condition into its designated well. Concentrated protein sample was centrifuged at
14,000xG for 15 minutes to remove any precipitated protein and 2µL was carefully added
to each well containing the optimized solutions. Plates were covered with a plastic lid
and left untouched for ~3 days and then observed for crystal growth each day. Scores
were made based on the amount and type of precipitate seen.

2.5.3 Sitting Drop
Crystallization screens were set up using a 96-well deep well plate. Selected
conditions from various Qiagen and Hampton Research Crystallization Screen Kits
(Table 3) were used to screen with SIKE 72 S6A (3.95mg/mL) for crystal formation.
About 0.5mL of each selected condition was dispensed in the reservoir of its designated
well. 0.2µL of the protein was loaded into the smaller sample well and topped with
0.2µL of the condition from the reservoir. The plate was carefully covered with optically
clear sealing film and left untouched for ~3 days before being observed for crystal
growth. Scores were made based on the amount and type of precipitate seen.

	
  

	
  
Table 3: Qiagen/Hampton Research screen kits and their corresponding Screen
Hit/condition numbers used in sitting drop crystallization trials.
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2.5.4 HWI screen
A sample of SIKE 72 S6A (12.9 mg/mL) and one sample of plain filtration buffer
were sent to HWI’s High-Throughput Crystallization Lab to be screened with their
available conditions and photographed daily for crystal formation. 0.2µL of the protein
sample was combined with 0.2µL of each HWI condition; a control was also set up using
0.2µL of plain buffer instead of protein sample. These wells were photographed weekly
and observed electronically for the appearance of crystals or changes in precipitate
formation.

2.6 Hydrogen-Deuterium Exchange
Total volume of protein needed was determined by the amount of time points
desired (~2 µL for each). Protein samples (between 4 and 12mg/mL) were diluted, 2:18,
with deuterium oxide (2H2O or D2O) at room temperature, and a timer was started. At
each scheduled time point, 20µL of exchanged sample was removed and quenched with
180µL of TFA-d (deuterated trifluoroacetic acid) and immediately frozen on ice. Time
points used for our testing were 0sec, 30sec, 1min, 1.5min, 2min, 3min, 5min, 10min,
15min, 30min, 45min, 1hr, 1.5hr, 2hr, 3hr, 4hr, 5hr, 6hr, 7hr, and 8hr. Exchanged
samples were stored on dry ice until analyzed. D2O exchange matrix buffer was made
(50µL TFA-d, 200µL D2O, 250µL acetonitrile, and 5-10mg sinapinic acid) and used to
pre-spot MALDI plate for each sample including one for a control (phosphate buffer) and
one for a calibration (bovine serum albumin (BSA)) sample. Plate was then vacuumed in
a desiccator for ~20 minutes until pre-spots were dry. Results are best when exchange
between samples and atmosphere is minimized following quenching, so tubes were kept
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tightly sealed when not in use. 5µL of each exchanged sample was thawed and added to
5µL of matrix buffer. This was mixed quickly before plating 2µL on designated pre-spot
on the plate. 2µL of BSA sample, phosphate buffer sample, and exchange samples from
each time point were plated twice in case one could not be read properly. Once complete,
plate was vacuumed in desiccator for another 20 minutes, until spots are dry. Time
points were analyzed using MALDI-TOF (matrix assisted LASER desorption/ionizationtime of flight), taking 1000 profiles for each spot.

2.7 Pepsin Digest
Total protein needed for all time points was calculated. Protein samples were
diluted 1:100 with 50mM phosphate buffer to the same concentration as the deuterium
exchange samples after being quenched with TFA-d. 50% immobilized pepsin mixture
(Pierce) was re-suspended and 0.25mL was added to 4mL of digestion buffer (20mM
sodium acetate, pH 3.5). Mixture was centrifuged at 1000xG for 5 minutes. Supernatant
was discarded and pellet was re-suspended in another 4mL of digestion buffer before
another 5 minutes of centrifugation at 1000xG. Supernatant was discarded and pellet was
brought up in 0.5mL of digestion buffer. The pepsin mixture was then added to 0.5mL of
diluted protein sample and left to incubate by shaking or inversion at 37oC. At each
scheduled time point, 50µL was removed and pepsin was separated from the protein
through centrifugation at 3,000xG for 3 minutes. Time points used for our testing were
0min, 1min, 5min, 10min, 15min, 30min, 1hr, 2hr, and 8hr. Supernatant, containing
protein sample, was then removed and stored at room temperature until plated. Pepsin
digest matrix buffer was made (5-10mg α-cyano-4-hydroxycinnamic acid dissolved in
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500µL of 50% D2O, 50% acetonitrile, and 0.1%TFA) and used to pre-spot MALDI plate
for each sample and low-molecular-weight calibration standards. The plate was then
vacuumed in the desiccator for ~20 minutes until pre-spots were dry. 5µL of each digest
time point sample was added to 5µL of matrix buffer. This was mixed before plating 2µL
on designated pre-spot on the plate, two spots for each sample were used. Standards were
plated for low-molecular-weight calibration, along with each time point sample. Once
complete, plate was vacuumed in desiccator for another 20 minutes, until spots were dry.
Time points were analyzed using MALDI-TOF, taking 1000 profiles for each spot. All
theoretical fragments that can result from pepsin digest of SIKE 72 S6A were acquired
(Protein Prospector) used to compare with experimental digest data.
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Chapter 3: Results

3.1 Original SIKE Expression and Identification of Contamination
As indicated in the methods section, the original protocol included protein
expression in E. coli grown from regular LB, chemical cell lysis in GudHCl, refolding on
Ni-NTA resin, polishing through SEC, and centrifugal concentration. Expression of
SIKE FL S6A was confirmed (after refolding) using SDS-PAGE, showing bands at
~29kDa (Figure 6a), which is standard for this protein weighing only 25,788 Daltons.
All gels were silver stained to confirm purity of the sample. Expression of SIKE 72 S6A
was confirmed using the same technique. Typical for this 17,964 Dalton protein, SIKE
72 S6A bands were seen at ~18kDa (Figure 6b). Also seen in the SIKE 72 S6A gel is an
unknown band at ~29kDa (Figure 6b) that eluted in three of the six fractions. Due to the
fact that this contaminant could be covered by the bands of interest for the full-length
construct (also runs at ~29kDa), we chose to continue most of the study using SIKE 72
S6A to be sure that we collected pure samples only.
To further polish the samples by separating them based on size and shape, NiNTA elution fractions were subjected to SEC. Figure 7a shows an SEC chromatogram
from one SIKE 72 S6A Ni-NTA elution fraction (E2 from Figure 6b). The protein that
eluted first (peaks labeled “1”) represents aggregate SIKE 72 S6A protein, while protein
that eluted second (peaks labeled “2”) was determined to be monomers/dimers of SIKE
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72 S6A. However, SDS-PAGE revealed the existence of the same ~29kDa contaminant
that was present in the original sample (Figure 7b). Previously, contamination at this
level had not been observed and could possibly have been overlooked due to the fulllength protein running at the same molecular weight in SDS-PAGE. In addition to using
pure SIKE protein for crystallization trials, we elected to devote some time to modifying
the existing purification procedure to maximize pure protein yield.

	
  

	
  

41	
  

Figure 6: SDS-PAGE results of unmodified purification protocol and identification
of contamination.
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Figure 7: SEC performed on SIKE 72 S6A (Figure 6b, fraction E2), purified using
the original protocol

Figure 7: SEC performed on SIKE 72 S6A (Figure 6b, fraction E2), purified using
the original protocol. (Top) Chromatogram showing Peak 1, aggregates of proteins, and
Peak 2, monomer/dimer SIKE species. (Bottom) SDS-PAGE shows SIKE 72 S6A in all
fractions and contamination found in peak 2 fractions.
	
  

	
  

43	
  

3.2 Auto-induction media increased soluble protein yield; growth at 16oC did not
One way to amplify the protein yield was to use auto-induction media to induce
expression of our protein more efficiently. Different metabolites in the media function to
promote cell growth to a high density and automatically stimulate protein expression
from IPTG-inducible lac promoters. Figure 8 shows SDS-PAGE analysis from
expressions using the original LB or the new auto-induction media. The new autoinduction media successfully increased the overall yield of pure SIKE 72 S6A from an
average of ~18 mg per 1L of cell culture to over 53 mg per L culture (~3 fold more
protein).
Growth at 16oC is known to help reduce aggregation during folding of
recombinant proteins23. Once cells reach an OD600=0.6-1.0, cells are immediately put on
ice to cool before being induced with 1mM IPTG and then grown overnight at 16oC.
This helps induce cold shock proteins and chaperones that are active at lower
temperatures. SIKE is expressed as insoluble protein in inclusion bodies- this approach
was used to examine if lower temperatures could allow SIKE to be expressed as soluble
protein. Nonetheless, this method was unsuccessful in increasing the amount of soluble
protein and decreasing the amount of aggregate protein (data not shown). For the
remainder of these studies, auto-induction media was used for induction of SIKE
expression in E. coli grown at 37oC.
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Figure 8: Results of SIKE 72 S6A expression with original LB media and autoinduction media.

Figure 8: Results of SIKE 72 S6A expression with original LB media and autoinduction media. SDS-PAGE shows considerably more SIKE 72 S6A expression using
auto-induction media (bottom) than regular Luria Broth (top).
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3.3 Sonication, but not freeze-thaw lysis, decreased amount of soluble contaminant
Proteins that are being over-expressed, like SIKE 72 S6A, are often stored inside
intracellular structures called inclusion bodies24. These inclusion bodies generally
contain very little host protein, suggesting that harvesting SIKE protein from inclusion
bodies could minimize contamination. Solubility test results showed most of the SIKE
72 S6A in the insoluble pellet sample, while the contaminant showed up solubilized in
the supernatant (Figure 9). Figure 10 shows SDS-PAGE analysis from protein harvesting
using the original chemical lysing protocol and the new sonication protocol. Although
the first three elution fractions still contained the contaminant, the level of contamination
was reduced. Freeze-thaw lysis was ineffective in reducing the amount of contaminant
(data not shown). For the remainder of these studies, sonication was used to remove as
much soluble contaminant as possible before harvesting inclusion bodies (insoluble
portion) for chemical re-suspension.

	
  

	
  
Figure 9: Solubility test results.

Figure 9: Solubility test results. Most of the SIKE 72 S6A is found in the insoluble
pellet sample (bottom arrow), while the contaminant showed up solubilized in the
supernatant (top arrow).
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Figure 10: Results of SIKE 72 S6A harvesting using chemical or sonication cell lysis.

Figure 10: Results of SIKE 72 S6A harvesting using chemical or sonication cell lysis.
SDS-PAGE shows more soluble contaminant when chemical lysis was used (top) than
when sonication is used for cell lysis (botom).
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3.4 Anion and cation exchange were unsuccessful in separating bacterial
contaminant from SIKE.
Ion exchange chromatography is based on the reversible interaction between a
charged protein and the oppositely charged chromatography medium used
(http://www.gelifesciences.com). Based on the amino acid sequence, the estimated
isoelectric point (pI) for SIKE 72 S6A is 6.2, so the anion buffer had a pH of 9.0, to
ensure de-protonation of accessible acid groups; and the cation exchange buffer had a pH
of 4.5, to ensure protonation of all basic groups. In this study, elution of proteins used an
increasing gradient of NaCl to compete with the charge-charge interaction between
protein and resin. It was hypothesized that SIKE and the contaminant would elute off of
the column at different times as the NaCl concentration gradually increased from 50mM
to 1M.
Figure 11 shows results from the first anion exchange attempt using IMAC
elution fraction E1 from an auto-induction/sonication prep (E1 from Figure 10). SDSPAGE and silver staining was used to confirm that the contaminant was successfully
separated from the target SIKE protein; however, the flow-through was not collected so it
could not be analyzed and all additional anion exchange trials were all unsuccessful in
separating the two proteins (data not shown).
Figure 12 shows results from a cation exchange attempt using IMAC elution
fraction E3 from an auto-induction/sonication prep (E3 from Figure 10). SDS-PAGE and
silver staining was used to confirm that cation exchange was unsuccessful in separating
the contaminant from target SIKE protein, as the ~29kDa protein is visible in both
fractions labeled 1 and 2.
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Figure 11: Anion exchange performed on SIKE 72 S6A (Figure 10, fraction E1).
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Figure 11: Anion exchange performed on SIKE 72 S6A (Figure 10, fraction E1).
Chromatogram shows separation of two species using a MonoQ XL column and a NaCl
gradient. Peak 1 (monomer/dimer SIKE species) proved to be pure using SDS-PAGE
and silver staining techniques.
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Figure 12: Cation exchange performed on SIKE 72 S6A (Figure 10, fraction E3).

Figure 12: Cation exchange performed on SIKE 72 S6A (Figure 10, fraction E3).
Chromatogram shows separation of two groups using HiTrap SP XL column and a NaCl
gradient. Both peak 1 (aggregate protein) and peak 2 (monomer/dimer SIKE species)
proved to be contaminated using SDS-PAGE and silver staining techniques.
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3.5 TALON® resin successfully binds SIKE and not contaminant
NiNTA elution fraction E2 (from figure 10) was used for IMAC with TALON®
resin. SDS-PAGE shows positive binding of both (re-folded) SIKE and SlyD proteins
(Figure 13). A significant amount of the SIKE did not bind the column and was found in
the flow-through sample (FT), but was also visible in all six elution fractions.
Additionally, contamination was only observed in the first elution fraction (E1). SEC
analysis of the fractions indicated that the FT was primarily SIKE aggregate protein (data
not shown), but elution fractions 2-6 were pure samples of SIKE monomer/dimer species
(Figure 14). These were combined and concentrated for crystallization trials.
SDS-PAGE from IMAC shows positive binding of (denatured) SIKE protein, but
no binding of (denatured) SlyD with TALON® resin (Figure 15). SlyD was seen in the
flow-through portions, indicating that it was present in the sample originally, but failed to
interact with the cobalt ions on the resin. SEC and SDS-PAGE analysis of elution
fractions confirmed the purity of all SIKE samples (Figure 16; E4 results shown). In
addition to eliminating contamination, the proportion of SIKE monomer/dimer species
had increased substantially compared to the trials with re-folded protein samples. This
allowed us to focus on concentrating the protein from our peak of interest and continue
more crystallization trials.
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Figure 13: SDS-PAGE results from IMAC with refolded proteins and TALON®
resin (Figure 10, fraction E2).

Figure 13: SDS-PAGE results from IMAC with refolded proteins and TALON®
resin (Figure 10, fraction E2). Resin bound both (re-folded) SIKE and SlyD proteins,
however, SlyD eluted mainly in the first elution fraction (E1).
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Figure 14: SEC performed on purified SIKE sample (Figure 10, fraction E2).
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Figure 14: SEC performed on purified SIKE sample (Figure 10, fraction E2).
Chromatogram shows elution of SIKE oligomer species, labeled with a number 1. SDSPAGE/silver stain performed on Peak 1 fractions confirm that fractions E2-E6 were
purified SIKE 72 S6A protein
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Figure 15: SDS-PAGE results from IMAC with denatured proteins and TALON®
resin.

Figure 15: SDS-PAGE results from IMAC with denatured proteins and TALON®
resin. Resin bound denatured SIKE only; SlyD can be seen in the soluble supernatant
portion (Sol.) before IMAC, and flow-through portion (FT) that did not bind the resin.
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Absorbance @ 280nm, mAU

Figure 16: SEC performed on purified SIKE sample (Figure 15, fraction E4).
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Figure 16: SEC performed on purified SIKE sample (Figure 15, fraction E4).
Chromatogram shows Peak 1 (aggregates of SIKE protein) and Peak 2 (SIKE
monomer/dimer species). SDS-PAGE performed on fractions confirms the purity of our
samples.
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3.6 Concentration of SIKE 72 S6A and crystallization trials
SEC fractions were pooled according to when they eluted during SEC in order to
separate different SIKE species (monomer/dimer, aggregate, etc). Centrifugation
concentration (with 10,000 Da molecular weight cut off filter) was used to remove buffer
from the pooled fractions. Concentration was stopped immediately when any precipitate
became visible in the sample, because further centrifugation would most likely precipitate
more of the soluble protein. Through numerous expression and protein harvesting
procedures, final concentrations ranged anywhere from less than 1mg/mL to over
20mg/mL, however, concentrations over 10mg/mL were rarely achieved for SIKE 72
S6A samples (data not shown). As soon as centrifugation was stopped, crystallization
trays were set.
Prior to this current study, a sample of SIKE 72 S6A was sent to HWI to be
screened using high-throughput crystallization methods and examined with 1,534
different conditions. Crystal formation was observed in various conditions, three of
which were chosen for optimization and further crystallization trials: 337, 371, and 863
(Table 2.1). All three conditions contained sodium acetate salt (0.1M) dissolved in buffer
(pH 5.0) and PEG (polyethylene glycol) 4,000 or PEG 8000 (40%w/v). These were
optimized to find the most favorable condition for SIKE crystal formation by altering the
pH and PEG concentrations, making 16 different conditions from each HWI condition
(Table 2.2).
Vapor diffusion experiments were completed using sitting drop plates and various
crystal screening kits to identify additional crystallization conditions. No single-crystal
formation was observed in any of the sitting drop plates with SIKE 72 S6A concentrated
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to 3.95mg/mL (data not shown). However, amorphous microcrystalline structures and
needle-like structures were observed in numerous conditions for all five screens (data not
shown).
Batch crystallization experiments were conducted to minimize any influence from
the outside environment by covering the conditions with paraffin oil. Figure 17 shows
examples of SIKE 72 S6A crystals that were obtained prior to identification of SlyD
contamination (top images) and SIKE 72 S6A precipitate that was observed in most wells
during the most recent protocol-modifying purification trials (bottom images). Original
SIKE 72 S6A crystals were rod shaped and formed from areas of dense protein
precipitation. For the majority of recent trials, protein precipitation was observed in
almost every condition. The volume of precipitated protein observed in each well
increased with higher concentrations of protein samples, yet X-ray diffraction quality
crystals were rarely observed. Only two crystals were observed in batch crystallization
trials during this study (Figure 18); however, they were not collected for any seeding or X
ray diffraction experiments. Both crystals were seen using protein sample obtained from
the protocol modified up to this point only.
To improve protein concentration, lyophilization was performed as a dehydration
method to evaporate buffer from the sample, leaving only protein and any other solutes.
Once completed, the remaining powder was brought up to ~15mg/mL in either 50mM
phosphate buffer (for MALDI experiments) or gel filtration buffer (to set up
crystallization plates). Not all of the protein was soluble, however this method greatly
increased both the final concentrations and volumes of the pure protein samples. Final

	
  

	
  
purified SIKE 72 S6A samples ranged from 10-15mg/mL (data not shown) and were
used for further structural analysis.
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Figure 17: Previous and current crystallization trials.

Figure 17: Previous and current crystallization trials. Top row, Crystals (indicated by
white arrows) obtained prior to the identification of SlyD contamination. Bottom row,
precipitate observed in current crystallization trials with the modified protocol.

	
  

	
  
Figure 18: Crystals from current SIKE 72 S6A trials.

Figure 18: Crystals from current SIKE 72 S6A trials. Crystals (indicated by white
arrows) obtained using the procedure with all protocol modifications up to this point
except lyophilization.
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3.7 Mass Spectrometry and Structural Analysis
In addition to crystallization trials, Hydrogen-Deuterium exchange was
investigated, accompanied with pepsin digests, in order to further characterize SIKE
structure. To confirm that this method could be useful, 0 and 24 hour HDX were
performed for both SIKE FL S6A (Figure 19) and SIKE 72 S6A (Figure 20). After 24
hours, an increase in molecular weight was observed for both constructs, indicating that
elucidation of structural information is possible through additional amide exchange,
digest, and analysis experiments. The overall increase in molecular weight was observed
to be 144 Daltons for the full-length construct (13,032 to 13,176 Daltons), and 293
Daltons for the truncated construct (17,886 to 18,179 Daltons).
To uncover structural information, fast, medium, and slow exchange of different
amide protons in the protein’s 3-demensional structure was investigated. Figure 21
shows the increase in molecular weight over 8 hours of HDX with SIKE 72 S6A. A large
portion (~60%) of the total exchange occurred within the first 30 minutes, however,
additional deuterium exchange was observed between 1-4 hours and 5-6 hours. The data
suggest that a stable tertiary structure exists, protecting some portion of hydrogen from
exchangingreadily.
In order to identify the location of HDX, pepsin digests must be completed with
both protein that has undergone exchange and protein that has not. Un-exchanged SIKE
72 S6A protein was digested with pepsin and sampled at time points between 0-2 hours
and at 8 hours. Spectra from each time point up to 2 hours are shown in Figure 22 and
display successful protein digestion; at 8 hours, the protein was fully digested (data not
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shown). This data will be used to determine a time point for reproducible digestion that
allows for identification of the largest percent of SIKE peptides.
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Figure 19: Hydrogen-deuterium exchange for SIKE FL S6A (0 and 24hr).
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Figure 19: Hydrogen-deuterium exchange for SIKE FL S6A (0 and 24hr). Change in
molecular weight of SIKE FL S6A due to hydrogen-deuterium exchange was observed
using MALDI from 0 hours (red line) to 24 hours (purple line).
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Figure 20: Hydrogen-deuterium exchange for SIKE 72 S6A (0 and 24hr).
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Figure 20: Hydrogen-deuterium exchange for SIKE 72 S6A (0 and 24hr). Change in
molecular weight of SIKE 72 S6A due to hydrogen-deuterium exchange was observed
using MALDI from 0 hours (red line) to 24 hours (purple line).

	
  

	
  
Figure 21: Deuterium exchange 8-hour time course for SIKE 72 S6A.

Figure 21: Deuterium exchange 8-hour time course for SIKE 72 S6A. Change in
molecular weight of SIKE 72 S6A due to hydrogen-deuterium exchange was measured
over an 8-hour time course.
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Figure 22: Pepsin digest of SIKE 72 S6A (0-2 hours)

Figure 22: Pepsin digest of SIKE 72 S6A (0-2 hours). SIKE 72 was digested with
pepsin for the indicated time periods; peaks signify peptide fragments.
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Chapter 4: Discussion

TLR-3-mediated signaling (through TBK1) initiates the innate immune response
by recruiting immune cells to the site of infection, inhibiting pathogen replication,
inducing apoptosis of infected cells, and communicating danger signals to other nearby
cells 1. Because of its importance in innate immunity, many studies concentrate on the
pathway involving IRF3 activation, the transcription factor that functions in production of
type 1 interferons. SIKE, a recently identified protein, is thought to play a role in this
pathway and has been the focus of study.
SIKE is an evolutionarily conserved, 207-amino acid protein that is part of an
uncharacterized family of proteins like fibroblast growth factor receptor 1 oncogene
partner 2 (FGFR10P2)2,18,20. It was shown that SIKE associates with TBK1 under normal
physiological conditions, but dissociates upon viral infection and TLR3 stimulation18,19.
SIKE did not disrupt any interactions required by proteins for TLR3-mediated NF-κB
activation, suggesting that SIKE specifically inhibited the IKKε- and TBK1-mediated
IFN-β activation pathways19. In addition, previous fluorescent microscopy studies show
SIKE (fused to GFP) accumulating in actin/cytoskeleton-like structures at the cell
periphery18. It is hypothesized that SIKE, in response to pathogen challenge, functions in
cytoskeletal rearrangement through phosphorylation by TBK1.
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Seeking to characterize the competition between TBK1 substrates, IRF3 and

SIKE, the Bell Laboratory previously determined that SIKE functions as a mixed type
inhibitor with respect to IRF3 phosphorylation18. Study of its protein composition
indicated that SIKE could be phosphorylated at six different sites, four of which resemble
phosphorylation sites on IRF325-27. Using these findings, the Bell Lab proposed that SIKE
functions, not only as an inhibitor of TBK1-mediated phosphorylation of IRF3, but also
as a TBK1 substrate (Figure 5). It is believed that SIKE, acting as a substrate, inhibits the
ability of TBK1 to phosphorylate IRF3, thus inhibiting type 1 interferon production18.
The function of phosphorylated SIKE once it has been released by the kinase remains
unknown and is the basis of this research. As such, understanding the structure of SIKE
through crystallographic and mass spectrometric methods may provide insight into its
function in the TLR-3 pathway mediated by IRF3 activation.
In the current study, SIKE FL S6A and SIKE 72 S6A (~18 kDA) were
successfully expressed using the original protein preparation protocol, however
contamination by an unknown protein was identified in our samples (Figure 6b). Due to
the fact that this contaminant ran at the same molecular weight in SDS-PAGE as the fulllength construct (both ~29kDa, Figure 6), we chose to continue most of the study using
SIKE 72 S6A to be sure that we collected pure samples only. The unknown protein was
found to contaminate E1-E3 from SEC trials, leaving only three pure SIKE fractions (E4E6) for crystallization trials and structural analysis. Protein that eluted first off of the
SEC column (peaks labeled “1”) represents aggregate SIKE 72 S6A protein, while
protein that eluted second (peaks labeled “2”) was determined to be monomers/dimers of
SIKE 72 S6A. Supporting these results, SIKE’s peptide sequence and predicted structure
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suggest that it can interact with itself to form multimers such as dimers or tetramers. The
contaminated fractions were used in various experiments with the goal of developing a
more efficient protocol for the purification of SIKE 72 S6A.
To amplify yield for inducible protein expression in E. coli, auto-induction media
was tested. Different metabolites in this media function to promote cell growth to a high
density and automatically stimulate protein expression from IPTG-inducible T7 lac
promoters28,29. This serves as an advantage by eliminating the need to monitor the
growth of cell cultures after inoculation. Glucose in the media prevents uptake of lactose
until the glucose is depleted, which is typically mid to late log phase. At that point, the
lactose is taken up by the cells and converted into allolactose by β-galactosidase.
Allolactose binds the lac repressor and causes it to release from the DNA. The T7 RNA
polymerase can then bind and begin to induce genes controlled by the lac promoter.
Such timely induction results in an increase in protein expression and overall yield. Once
the concentration of lactose becomes low, glycerol in the media serves as the late energy
source and the lac promoter is no longer induced29. In our experiments, auto-induction
media successfully increased the yield of protein by almost 3 fold (Figure 8). Although
the media efficiently increased protein expression, contamination was still observed in
SEC elution fractions E1-E3.
One obstacle with the over-expression of recombinant protein in bacterial cells is
formation of cytoplasmic aggregates in inclusion bodies30. At higher temperatures,
aggregation of proteins is driven by hydrophobic interactions23. Growth at 16oC is
known to help reduce aggregation during folding by increasing the activity of cold shock
protein that function as chaperones to aid in protein folding23,30. One disadvantage is that
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a sudden decrease in temperature slows replication, transcription, and translation.
Ultimately, this method proved unsuccessful in increasing the amount of soluble protein
and decreasing the amount of aggregate protein (data not shown). For the remainder of
these studies, E. coli was grown at 37oC as noted in the original protocol.
Proteins being over-expressed are often stored inside intracellular structures
called inclusion bodies24. These inclusion bodies generally contain very little host
protein, suggesting that harvesting SIKE protein directly from inclusion bodies could
minimize contamination. One method used to isolate inclusion bodies is to lyse the
plasma membrane through a series of flash freezing and thawing31. Fragmentation of the
membrane allows inclusion bodies to be easily harvested through centrifugation,
separating them from any soluble contents. One possible disadvantage is that the
procedure could result in protein degradation or precipitation32. In this study, freeze-thaw
lysis proved ineffective in reducing the amount of contaminant in SIKE 72 S6A samples
(data not shown). Furthermore, overall SIKE 72 S6A protein yield was less than that of
the original protocol.
Another method recommended for harvesting protein from cell cultures,
sonication, uses a metal probe that generates ultrasonic waves to shear the plasma
membrane and release inclusion bodies24,33. The inclusion bodies can then be harvested
through centrifugation and solubilized to release the enclosed protein. One disadvantage
of sonication is excess heat generated from the high-energy waves can damage proteins,
lowering the final protein yield. Solubility test results showed most of the SIKE 72 S6A
in the insoluble pellet sample, while the contaminant separated to the soluble supernatant
(Figure 9), suggesting that this method may be useful in isolating the protein from the
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contaminant. Although fractions E1-E3 still contained the contamination, the overall
level of contaminant was reduced in each of the three fractions (Figure 10). For the
remainder of these studies, sonication was used to remove as much soluble contaminant
as possible before harvesting inclusion bodies (insoluble portion) for chemical lysis.
Ion exchange chromatography is based on the reversible interaction between a
charged protein and the oppositely charged chromatography medium used
(http://www.gelifesciences.com). Small differences in the surface charges of two
proteins causes them to elute at different points during the process. The surrounding
buffer pH largely influences a protein’s surface charge, as well as possible interactions
that the protein can make. For anion exchange, the buffer pH should be at least one unit
higher than the pI of the protein of interest to allow it to bind the positively charged solid
support. For cation exchange, the buffer pH should be at least one unit below the pI of
the protein of interest so it can bind the negatively charged solid support. Based on the
amino acid sequence, the estimated pI for SIKE 72 S6A is 6.2, so the anion exchange
buffer had a pH of 9.0 and the cation exchange buffer had a pH of 4.5. In this study,
elution of proteins used an increasing gradient of NaCl to compete with the proteins
binding to the column. As the NaCl concentration was gradually increased from 50mM
to 1M, different elution patterns for SIKE and the contaminant were hypothesized.
Although positive separation of the two species was observed for the first anion
exchange trial (Figure 11), all subsequent trials proved to be unsuccessful (data not
shown). Additionally, all cation exchange trials were unsuccessful in separating the two
proteins based on charge (Figure 12). Together, these results demonstrate that SIKE 72

	
  

	
  

72	
  

S6A cannot be successfully separated from the contaminant by either anion or cation
affinity chromatography.
Further research on the ~27kDa contaminant helped us identify it as a genomeencoded E. coli protein, named SlyD34. SlyD is a small (22,853 Daltons), cytosolic
protein that has 14 histidine residues clustered at the C-terminal end of the peptide
sequence (Figure 23). This amino acid composition results in contamination of
purification procedures that use Ni-NTA resin to bind his-tagged proteins.
Analysis of Ni-NTA elution fractions by SDS-PAGE showed positive binding
(E1-E3) of both SIKE and SlyD proteins to the resin (Figure 6). Clontech Laboratories,
Inc. advertises a resin, TALON®, which uses Co2+ metal ions instead of Ni2+ ions to bind
histidine residues. Contaminated Ni-NTA fractions were used to assess the efficiency of
the resin to bind (already refolded) SIKE 72 S6A. A significant amount of SIKE did not
bind the resin and was found in the flow-through, however, SlyD contamination was
limited to the first elution fraction (Figure 13). SEC analysis of the FT indicated that it
was primarily SIKE aggregate protein (data not shown), but elution fractions 2-6 from
these trials were determined to be pure SIKE monomer/dimer species (Figure 14). These
were combined and concentrated for crystallization trials. Together, these results suggest
that the SlyD residues are still interacting with the ions on the resin.
The amino acid sequence of SlyD (Figure 23) shows the histidine residues spread
throughout the C-terminus, suggesting that separation using TALON® resin may be
enhanced if the proteins were denatured and refolded on this resin, as opposed to using
previously-refolded protein. SDS-PAGE from IMAC shows positive binding of
denatured SIKE protein, but not denatured SlyD with TALON® resin (Figure 15). SlyD
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was seen in the flow-through portions, indicating that it was present in the sample
originally, but failed to interact with the cobalt ions on the resin. In addition to
eliminating contamination, SEC showed the proportion of SIKE monomer/dimer species
had increased substantially compared to the aggregate portion (Figure 16). This allowed
us to focus on concentrating the protein from our peak of interest and continue
crystallization trials.
Proteins that eluted at different times during SEC were pooled separately in order
to separate SIKE species (monomer, dimer, etc). Following coentrifugation, final sample
concentrations ranged from less than 1mg/mL to over 20mg/mL, however, SIKE 72 S6A
samples over 10mg/mL were rarely attained (data not shown). When centrifugation was
stopped, crystallization trays were set.
In supersaturated solutions, small protein particles (seeds) stimulate separation of
the solute from the solvent; this is called precipitation. This process is influenced by the
contents, concentration, and pH of a solution, as well as environmental conditions. The
point when the concentration becomes ideal for crystal formation is known as the
“nucleation point.” Structure and charge of a protein determine the possible ways in
which they can interact when they precipitate out of a solution35. Crystal formation
requires the diffusion of protein from an aqueous liquid to a pure-solid crystalline phase.
It is known that specific 3-dimensional repeating protein patterns (monomers/ multimers,
complexes, subunits, etc) form crystals if they precipitate in well-defined size and
shape36. Precipitation that occurs with a less-ordered arrangement of protein species
produces amorphous structures. To help draw the protein out of solution, precipitants can
be used in the crystallization experiments.
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Prior to this current study, a sample of SIKE 72 S6A was sent to HWI to be

screened using high-throughput crystallization methods and examined with 1,534
different conditions. Crystal formation was observed in various conditions, three of
which were chosen for optimization and further crystallization trials: 337, 371, and 863
(Table 1). All three conditions contained sodium acetate salt (0.1M) dissolved in buffer
(pH 5.0) and PEG 4,000 or PEG8000 (40%w/v). These were optimized to find the most
favorable condition for SIKE crystal formation by altering the pH and PEG
concentrations, making 16 different conditions from each HWI condition (Table 2.2).
Vapor diffusion experiments were completed using sitting drop plates and various
crystal screening kits to identify additional crystallization conditions. Sitting drop plates
use a reservoir well for the crystallization condition and a small well for the protein
sample that is covered by the same condition in the reservoir well. This method is
designed to allow diffusion of water vapor out of the sample, increasing the concentration
of the protein (as well as the precipitant) until equilibration is achieved, ideally around
the nucleation point35. No single-crystal formation was observed in any of the sitting
drop plates with SIKE 72 S6A concentrated to 3.95mg/mL (data not shown). However,
amorphous microcrystalline structures and needle-like structures were observed in
numerous conditions for all five screens. Analysis of those conditions revealed certain
common denominators: TRIS or HEPES as the buffer, PEG 4000 or 8000 (25-30% w/v)
as the precipitant, and ammonium sulfate or sodium acetate as the salt. This was similar
to the results from HWI, suggesting that these might be favorable conditions for
obtaining SIKE 72 S6A crystals, but protein concentration may be too low.
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Batch crystallization experiments were conducted to minimize any influence from

the outside environment by covering the conditions with paraffin oil. Vapor
diffusion/equilibration is minimized; therefore this method requires protein to be
introduced directly to conditions around its nucleation point. Beginning 3 days after the
trays were completed (to allow time for any crystal formation), plates were observed
daily. Although crystals were obtained from crystallization trials before the identification
of SlyD contamination (Figure 17, top row), current batch crystallization trials have
mostly been unsuccessful in producing x-ray diffraction quality crystals with SIKE 72
S6A samples from the modified protocol (Figure 17, bottom row). Original SIKE 72
S6A crystals were rod shaped and formed from areas of dense protein precipitation. For
the majority of recent trials, protein precipitation was observed in almost every single
condition. The volume of precipitated protein observed in each well increased with
higher concentrations of protein samples, yet no X-ray diffraction quality crystals were
observed. This suggested that pure protein samples still might not be concentrated
enough to allow any crystal formation.
To improve protein concentration, lyophilization was performed as a dehydration
method to evaporate water from the sample, leaving only protein and any other solutes.
Once completed, the remaining powder was brought up to ~15mg/mL in either 50mM
phosphate buffer (for MALDI experiments) or gel filtration buffer (to set up
crystallization plates). Not all of the protein was soluble, however this method greatly
increased both the final concentrations and volumes of the pure protein samples. Final
purified SIKE 72 S6A samples ranged from 10-15mg/mL (data not shown) and were
used for more crystallization trials and additional structural analysis.
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In addition to crystallization trials, Hydrogen-Deuterium exchange was

investigated, accompanied with pepsin digests, in order to further characterize the
location of HDX using Mass Spectrometry. Native proteins are typically found in tightly
folded conformations; understanding these structures is essential to infer a protein’s
function. One method used to understand protein conformation is to use hydrogendeuterium exchange followed by pepsin digestion and peptide analysis by mass
spectrometry. Deuterium (D2) is an isotope of hydrogen that freely exchanges with
hydrogen atoms on proteins. The extent to which peptides in the protein are shielded
from the solvent, and whether they participate in intra-molecular hydrogen bonding
determine the rate at which the amide protons undergo exchange37. By identifying where
HDX is possible in the SIKE sequence, we identify solvent-exposed or flexible structural
regions.
To confirm that this method could be useful, 0 and 24 hour exchanges were
performed for both SIKE FL S6A (Figure 19) and SIKE 72 S6A (Figure 20). After 24
hours, an increase in molecular weight was observed for both constructs, indicating that
elucidation of structural information is possible through additional peptide exchange,
digest, and analysis experiments. The overall increase in molecular weight was observed
to be 144 Daltons for the full-length construct (13,032 to 13,176 Daltons), and 293
Daltons for the truncated construct (17,886 to 18,179 Daltons).
To uncover structural information, time points from 0 hours to 8 hours were used
in deuterium exchange to determine when fast, medium, and slow exchange occurs for
SIKE 72 S6A. Protons exposed to the solvent generally exchange with the environment
faster than ones buried inside the structure. Identifying amino acids/ peptides located on
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the surface requires uncovering which residues underwent fast exchange. Over the first
30 minutes, deuterium atoms had already replaced ~164/293 (56%) of the protons in
SIKE 72S6A available for exchange (using 24hr. as “full exchange;” Figure 20).
Analysis of SIKE 72 S6A peptide sequence reveals that ~179 amide protons are available
for fast exchange, 17 of which are located on arginine/lysine side chains. It is known that
amide protons of arginine/lysine are not as easily exchanged, leaving ~162 protons that
(theoretically) can be readily exchanged. Together, these results support the hypothesis
that different amino acids/peptides are exchanging hydrogen atoms at different rates.
Furthermore, exchange for SIKE 72 S6A displayed a step-wise pattern, consistent with
known (folded) proteins that undergo deuterium incorporation (Figure 21).
In addition to exchange, pepsin digests were performed to identify the ideal time
for SIKE digestion to yield adequately sized peptides for mass spectrometry analysis. An
ideal time is one that allows for the highest percent of peptide recovery for analysis, as
well as one that is reproducible. Ultimately, the proteins that have undergone fast,
medium, or slow exchange will be digested for the same time to yield the same set of
peptides for each sample. Mass spectrometry analysis on the peptides allows comparison
of exchanged and un-exchanged samples to identify which peptides exchanged more and
when that exchange occurred. All together, this information will help us locate the
peptides within the 3-dimensional protein structure that underwent exchange.
Pepsin digests of SIKE 72 S6A were performed for at time points between 0 and
2 hours, as well as one at 8 hours. Mass spectrometry analysis showed successful
digestion of protein, revealing fragments of various sizes between 500 and 5,000 Daltons
(Figure 22). A database search on the Protein Prospector website with the SIKE 72 S6A
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sequence revealed every potential peptide fragment that could be created from pepsin
digest of SIKE 72 (data not shown). Using this information, the ideal time for protein
digestion will be determined that yields an appropriate amount of fragments sufficient for
mass spectrometry analysis. With the ideal time point determined, SIKE 72 S6A protein
that has already undergone exchange will be digested and analyzed with mass
spectrometry. Molecular weight changes between exchanged and un-exchanged peptide
fragments will indicate the amount of deuterium that has been exchanged on that specific
peptide. Determining which peptides exchanged deuterium helps pinpoint the fragment
within the overall 3-dimensional structure of the protein that is accessible for exchange.
Peptides that undergo the fastest exchange are (most likely) positioned such that amide
hydrogen atoms are more exposed to the exchange solvent. The peptides observed to
exchange the least amount are (most likely) buried within the protein, making it difficult
to exchange hydrogen atoms with deuterium atoms in the solvent. Currently, only digest
of un-exchanged SIKE 72 S6A have been completed; subsequent digest for exchanged
protein and peptide fragment analysis will be needed to infer any information about the
proteins surface structure.
In this study, the purification of SIKE 72 S6A revealed an E. coli contaminant,
later identified as SlyD. The purification scheme was modified to remove contamination
and increase the quality of protein samples for crystallization trials. Auto-induction
media was effective in amplifying protein yield by over 3 fold. Harvesting inclusion
bodies by sonication (not freeze-thaw lysis) decreased the overall amount of SlyD in
IMAC fractions, however, contamination was still observed in the same samples. Cation
and anion affinity chromatography were both ineffective in separating the two proteins.
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TALON® resin bound both denatured SIKE 72 S6A and SlyD, however, only SIKE 72
S6A bound the resin under denaturing conditions, allowing successful separation from
the contaminant. Concentration issues were answered through the use of lyophilization
techniques, in place of ultrafiltration. Crystallization trials for samples from each
purification scheme were completed, but no X-ray diffraction quality crystals were
observed. In addition to crystallization trials, Hydrogen-Deuterium exchange
accompanied with pepsin digests, in order to further characterize the SIKE structure
where initiated. Additional exchange and digest trials must be completed to conclude any
structural information regarding the surface area of SIKE 72 S6A.
While these studies investigate the properties of recombinant SIKE using various
methods, the findings as a whole establish a previously undefined protocol for SIKE
purification that will further future structural studies.
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Figure 23: Amino acid peptide sequence for E. coli protein, SlyD.

SlyD"pep)de"sequence"

MKVAKDLVVSLAYQVRTEDGVLVDESPVSAPLDYLHGHGSLISGLETALEGHEVGDKFDVAVGANDAY3
GQYDENLVQRVPKDVFMGVDELQVGMRFLAETDQGPVPVEITAVEDDHVVVDGNHMLAGQNLKFN3
VEVVAIREATEEELAHGHVHGAHDHHHDHDHDGCCGGHGHDHGHEHGGEGCCGGKGNGGCGCH"
3

Figure 23: Amino acid peptide sequence for E. coli protein, SlyD. Highlighted in red
are 14 histidine residues located in the C-terminus of the protein sequence that cause it to
contaminate purification procedures that use Ni2+ ions to bind his-tagged proteins.
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